Extended Data Fig. 8: Therapeutic effects of αPD1-hEry treatment in participants.
a, Assessment of erythrocyte-related safety and systemic inflammation parameters at baseline and at multiple time points after αPD1-hEry treatment (n = 7 participants per dose level). Parameters included erythrocyte count, hemoglobin, total bilirubin (TBIL), indirect bilirubin (IBIL), direct bilirubin (DBIL), D-dimer, fibrinogen, white blood cells (WBCs) count, neutrophils, and lymphocytes. b-c, Pharmacokinetic analysis of αPD1-hEry in peripheral blood (n = 7 participants per dose level). b, Quantification of αPD1-hEry (human IgG⁺ CD235a⁺ cells) at indicated time points by flow cytometry. c, Measurement of free anti-PD1 antibody levels in plasma by MSD assay (P13 excluded due to insufficient plasma sample). d-e, Analysis of PD1 receptor saturation on peripheral T cells in patients treated with αPD1-hEry, assessed by flow cytometry. d, Baseline PD1 saturation in T cells from healthy donors (n = 5 donors) and enrolled cancer patients (n = 7 participants). e, Dynamic PD1 target saturation in T cells at 1 h and 504 h post-infusion, measured across treatment cycles (n = 3 participants per dose level). f, Combined t-SNE plot of total PBMCs from P3 and healthy donor (the data obtained from 10 x Genomics for reference), analyzed by scRNA-seq. g-h, Dot plots showing scaled expression values of discriminative gene sets per cluster as defined in total PBMCs (g) and myeloid cells (h). Data are presented as mean ± s.e.m.
